Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases

This study is testing whether delivering radioactive therapy directly into the liver's blood supply — rather than through a vein — can improve outcomes for patients with a type of slow-growing gut or pancreatic tumor (called a neuroendocrine tumor) that has mainly spread to the liver. **You may be eligible if:** - You have a confirmed neuroendocrine tumor originating from the gut or pancreas - Your disease has progressed despite standard treatment with a cold somatostatin analog - You have already completed 4 standard cycles of LUTATHERA (a radioactive therapy) - Most or all of your cancer is in the liver and cannot be surgically removed - You have acceptable blood counts, kidney, and liver function - You are 18 or older **You may NOT be eligible if:** - Your tumor showed a complete response (disappeared entirely) after LUTATHERA - You have significant cancer outside the liver that threatens your life - You have heart disease affecting your heart's pumping ability - You have liver cirrhosis or other conditions preventing safe delivery of therapy into the liver's arteries - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.